Lynne Sullivan - Feb 9, 2022 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)

Signature
/s/ Alexander Nguyen, Attorney-in-Fact for Lynne Marie Sullivan
Stock symbol
UBX
Transactions as of
Feb 9, 2022
Transactions value $
$0
Form type
4
Date filed
2/15/2022, 04:17 PM
Previous filing
Jul 30, 2021
Next filing
Mar 31, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UBX Common Stock, $0.0001 par value Award $0 +50K +18.06% $0.00 327K Feb 9, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UBX Stock Option (Right to Buy) Award $0 +200K $0.00 200K Feb 9, 2022 Common Stock 200K $1.06 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") one third of which vests on February 9, 2023 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
F2 Includes RSUs which vest over time measured from the grant date. Also includes 5,952 shares of Common Stock of the Issuer purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
F3 The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.